Atlas Trials

Pembrolizumab in Post Radical Operation ESCC Patients With Lymph Node Positive ( KEYSTONE-004 )

Clinical trial NCT04863079 · UNKNOWN

Trial details

NCT number
NCT04863079
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
ESCCAdjuvant TreatmentLymph Node PositivePembrolizumab
Start date
2021-05-01
Primary completion
2022-04-30
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.